Press Releases

Press Releases

or

August 1, 2013
(Aug 1, 2013, Beijing) – BeiGene, a biotechnology company focused on the discovery and development of innovative oncology treatment, announced collaboration with GENEWIZ, Inc., leading global genomics service provider. The two companies will work together to accelerate cancer biomarker discovery,
August 1, 2013
BPBC (Beijing Pharma and Biotech Center) deputy director Li Qiong has visited BeiGene to hear the report made by R & D team about working projects of this company. After the meeting, Li Qiong gave a high praise to the work of BeiGene. About BPBC BPBC was established in June 24, 1996, it aimed to
July 9, 2013
(July 09, 2013, Beijing) – BeiGene was conferred with “The Asia’s Best Employer Brand Award” at the fourth Asia’s Best Employer Brand Awards 2013 held on July 31, 2013 in Singapore. Asia’s best employer brand awards are hosted by Employer Branding Institute; World HRD Congress and Stars of the
July 7, 2013
Dr. Ye Liu, Principle Investigator of Molecular Sciences of BeiGene, received award of “New Star in Science and Technology” by Beijing Municipal Science and Technology Commission (BEIJING NOVA PROGRAM ). Dr. Lai Wang, Head of Discovery Biomarkers of BeiGene, also won the honor In 2011.
June 3, 2013
BeiGene and Merck KGaA, a top big pharma company have entered into a global licensing, co-development, co-promotion and commercialization agreement for BeiGene-283. The compound is a second-generation BRAF inhibitor for the treatment of cancer. BeiGene-283,which is currently in preclinical
June 1, 2013
BeiGene, a Beijing biopharma startup, out-licensed the ex-China rights for a pre-clinical cancer drug to Merck Serono, the drug discovery arm of Germany’s Merck KGaA (Xetra: MRK). To date, BeiGene has been in the news for acquiring China rights to western-developed drugs.
May 31, 2013
Merck Serono has signed a global licensing, co-development and commercialisation agreement with Chinese biotech BeiGene, for a cancer compound called BeiGene-283. The second-generation BRAF inhibitor is currently in preclinical development. BRAF inhibitors target a protein that is a downstream